Activating mutations to the PI3K-AKT-mTOR pathway essentially reprogram the cell’s metabolism, therefore targeting the unique metabolic dependencies of cancer cells through the PI3K-AKT-mTOR network may provide much therapeutic gain. Here, AKT1 is linked to cancer.